"Hematologic Diseases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Disorders of the blood and blood forming tissues.
- Hematologic Diseases
- Disease, Hematologic
- Diseases, Hematologic
- Hematologic Disease
- Blood Diseases
- Blood Disease
- Disease, Blood
- Diseases, Blood
- Hematological Diseases
- Disease, Hematological
- Diseases, Hematological
- Hematological Disease
Below are MeSH descriptors whose meaning is more general than "Hematologic Diseases".
Below are MeSH descriptors whose meaning is more specific than "Hematologic Diseases".
This graph shows the total number of publications written about "Hematologic Diseases" by people in this website by year, and whether "Hematologic Diseases" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
|Year||Major Topic||Minor Topic||Total|
To return to the timeline, click here.
Below are the most recent publications written about "Hematologic Diseases" by people in Profiles.
Implementation and Evaluation of Virtual Laboratory Tours for Laboratory Diagnosis of Hematologic Disease. Am J Clin Pathol. 2022 06 07; 157(6):801-804.
Post hoc analyses of GOG 9923: Does BRCA status affect toxicities?: An NRG oncology study. Gynecol Oncol. 2021 05; 161(2):512-515.
Diversity and severity of adverse reactions to quinine: A systematic review. Am J Hematol. 2016 May; 91(5):461-6.
Challenges and potential solutions for recruitment and retention of hematopoietic cell transplantation physicians: the National Marrow Donor Program's System Capacity Initiative Physician Workforce Group report. Biol Blood Marrow Transplant. 2014 May; 20(5):617-21.
Hematologic toxicities associated with intravenous immunoglobulin therapy. Int Immunopharmacol. 2011 Nov; 11(11):1663-7.
Relevance of JAK2V617F positivity to hematological diseases--survey of samples from a clinical genetics laboratory. J Hematol Oncol. 2011 Jan 14; 4:4.
A phase I trial of dose-dense (biweekly) carboplatin combined with paclitaxel and pegfilgrastim: a feasibility study in patients with untreated Stage III and IV ovarian, tubal or primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2010 Sep; 118(3):303-7.
Sterile neutrophilic folliculitis with perifollicular vasculopathy: a distinctive cutaneous reaction pattern reflecting systemic disease. J Cutan Pathol. 1998 Apr; 25(4):215-21.